BUZZ-Mirum Pharma gains after Evercore raises PT on liver drugs potential
Reuters03-04
BUZZ-Mirum Pharma gains after <a href="https://laohu8.com/S/EVR">Evercore</a> raises PT on liver drugs potential
** Shares of Mirum Pharmaceuticals MIRM.O rise 2.15% to $89.69
** Evercore ISI raises PT to $126 from $101 and reiterates an "outperform" rating
** MIRM "checks all the boxes" with its growing rare-liver disease portfolio plus upcoming data from multiple key trials, clear competitive outlooks, and a real margin expansion story, says Evercore analyst Gavin Clark-Gartner
** MIRM expects mid-stage data for experimental liver disease drug volixibat and interim late-stage data for hepatitis D drug candidate brelovitug in Q2 2026
** Brokerage expects global unadjusted peak sales of $1.2 billion for volixibat in primary sclerosing cholangitis, a rare, chronic, progressive liver disease
** MIRM shares rose over 91% in 2025
(Reporting by Kunal Das in Bengaluru)
((Kunal.Das2@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments